Canaccord Genuity Reiterates a Buy Rating on Advanced Accelerator Applications

By Ryan Adsit

In a report released today, John Newman from Canaccord Genuity reiterated a Buy rating on Advanced Accelerator Applications (NASDAQ: AAAP), with a price target of $47. The company’s shares opened today at $33.85.

According to, Newman is ranked 0 out of 5 stars with an average return of -10.3% and a 36.7% success rate. Newman covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Dimension Therapeutics Inc, and Aurinia Pharmaceuticals.

Advanced Accelerator Applications has an analyst consensus of Moderate Buy.

The company has a one year high of $39.66 and a one year low of $20.53. Currently, Advanced Accelerator Applications has an average volume of 108.5K.

Advanced Accelerator Applications SA is a radiopharmaceutical company which develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. It offers research and development in medicinal and pharmaceutical therapeutic products mainly focusing in cardiology and neurology. The firm manufactures both diagnostic and therapeutic MNM products for commercialization. The company was founded in 2002 by Stefano Buono and is headquartered in Saint Genis Pouilly, France.